@nejm : In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo. Read the full ATTRibute-CM trial results: nej.md/48tEoTH • TwiCopy

NEJM

@nejm

+ Follow

The New England Journal of Medicine is the world’s leading medical journal and website.

ID: 25950355

linkhttp://NEJM.org calendar_today23-03-2009 04:10:07

34,34K Tweet

934,934K Takipçi

430 Takip Edilen

NEJM

@nejm

2 years ago

In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo. Read the full ATTRibute-CM trial results: nej.md/48tEoTH

thumb_up_off_alt164

chat_bubble_outline1

repeat51

shareShare